2013
DOI: 10.1016/j.carbpol.2013.01.014
|View full text |Cite
|
Sign up to set email alerts
|

Galactosylated chitosan–polycaprolactone nanoparticles for hepatocyte-targeted delivery of curcumin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
34
1

Year Published

2014
2014
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 80 publications
(35 citation statements)
references
References 38 publications
0
34
1
Order By: Relevance
“…In this dimension, nanoscience and nanotechnology opens a very exciting window of opportunity via enabling the enhanced curcumin delivery through nanoscale carriers, carrying far lesser amount of the drug and promising a slow, targeted and gradual release. The delivery of curcumin through various nanocarriers including nanoparticles, nanoemulsions, nanosuspensions, nanofibers and many others has enabled a great deal of improvement in its systemic localized availability and the corresponding increase or amplification of its therapeutic and protective effects [49][50][51][52]. Studies have reported the enhanced benefits of curcumin delivered through nanoroutes to the extents of even 27 times [53].…”
Section: Nanotechnological Interventions To Enhance Bioavailability Omentioning
confidence: 99%
“…In this dimension, nanoscience and nanotechnology opens a very exciting window of opportunity via enabling the enhanced curcumin delivery through nanoscale carriers, carrying far lesser amount of the drug and promising a slow, targeted and gradual release. The delivery of curcumin through various nanocarriers including nanoparticles, nanoemulsions, nanosuspensions, nanofibers and many others has enabled a great deal of improvement in its systemic localized availability and the corresponding increase or amplification of its therapeutic and protective effects [49][50][51][52]. Studies have reported the enhanced benefits of curcumin delivered through nanoroutes to the extents of even 27 times [53].…”
Section: Nanotechnological Interventions To Enhance Bioavailability Omentioning
confidence: 99%
“…One of the effective targeting delivery approaches is to utilize some ligand-receptor interactions [75]. Receptor-targeted nanocarrier delivery mechanism has been shown to improve therapeutic responses both in vitro and in vivo [76].…”
Section: Ligand-receptor Chitosan Nanocarriersmentioning
confidence: 99%
“…This is due to the fact that asialoglyco-protein receptors on hepatoma cells can specifically bind with certain types of ligands containing specific terminals such as β-D-galactose and Nacetylgalactosamine residues [75].…”
Section: Ligand-receptor Chitosan Nanocarriersmentioning
confidence: 99%
“…Nevertheless, a simple blend of DOX and CUR will not be a favorable formulation for their combined use because CUR has poor aqueous solubility and low bioavailability; moreover, CUR could be rapidly cleared by the circulation. 19,20 To date, several nanocarriers involving liposomes, polyethylene glycol (PEG)-linked (PEGylated) polycaprolactone nanoparticles and chitosan/poly(butyl cyanoacrylate) nanoparticles have been used to deliver DOX and CUR together. [21][22][23][24] Although these nanocarriers have shown improved anticancer efficacy against different tumors, whether they have the potential to reverse MDR of cancer cells has not been examined.…”
mentioning
confidence: 99%
“…On the other hand, CUR is known to be hydrophobic, and in particular, it can be easily degraded under physiological conditions. 19,34 In contrast to free CUR, the loaded CUR in (DOX + CUR)-PMs would be completely protected from degradation before CUR gets into cells, and thus, more CUR molecules with sensitizing activity can finally be transferred into the cells during the endocytosis of (DOX + CUR)-PMs compared to the case of the simple combination of DOX and CUR. As a result, (DOX + CUR)-PMs result in enhanced cytotoxicity toward A549 cells, as shown in Figure 6.…”
mentioning
confidence: 99%